Casdin Capital’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.1M Sell
315,000
-65,000
-17% -$6.53M 2.2% 11
2025
Q4
$38.8M Buy
380,000
+280,000
+280% +$25M 2.41% 10
2025
Q3
$6.25M Hold
100,000
0.52% 22
2025
Q2
$5.2M Sell
100,000
-150,000
-60% -$6.7M 0.47% 22
2025
Q1
$10.7M Sell
250,000
-100,000
-29% -$4.31M 0.87% 20
2024
Q4
$10.7M Hold
350,000
0.71% 21
2024
Q3
$8.03M Buy
350,000
+250,000
+250% +$7.08M 0.54% 25
2024
Q2
$2.89M Buy
+100,000
New +$2.33M 0.22% 30
2022
Q3
Sell
-272,500
Closed -$11M 40
2022
Q2
$11M Sell
272,500
-147,500
-35% -$7.31M 0.93% 23
2022
Q1
$27.8M Sell
420,000
-370,000
-47% -$25.3M 1.25% 26
2021
Q4
$79M Buy
+790,000
New +$81.7M 2.23% 15

Other funds holding GH

Casdin Capital's GH Position: Q1 2026 in Review

Casdin Capital reduced its Guardant Health (GH) stake by 17% in Q1 2026, selling an estimated $6.53M and leaving 315,000 shares worth $29.1M. The position accounts for 2.2% of the portfolio, ranked #11.

Casdin Capital first reported a position in GH in Q4 2021 and has held it in 11 quarters since. The position peaked at $79M in Q4 2021. 482 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Casdin Capital held 315,000 shares of Guardant Health worth $29.1M as of Q1 2026.
  • Casdin Capital sold 65,000 Guardant Health shares in Q1 2026, an estimated $6.53M.
  • Guardant Health made up 2.2% of Casdin Capital's portfolio in Q1 2026, its #11 holding.
  • Casdin Capital first reported a position in Guardant Health in Q4 2021 and has held it in 11 quarters since.
  • Casdin Capital's Guardant Health position peaked at $79M in Q4 2021.
  • 482 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.